Development of a dual delivery of levofloxacin and prednisolone acetate via PLGA nanoparticles/ thermosensitive chitosan-based hydrogel for postoperative management: An in-vitro and ex-vivo study

Cheng, Yung Hsin; Chang, Yu Fan; Ko, Yu Chieh; Liu, Catherine Jui Ling

doi:10.1016/j.ijbiomac.2021.03.017

Cited by 26 publications

(19 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, the interaction between the LCH coating and epithelial cells not only opens the cell bypass pathway to prepare for drug penetration but also promotes cell penetration of drugs. 44,45 Current research shows that oxidative damage to the lens is the main cause of senile cataracts. Since the etiology of the selenium-induced cataract model is similar to that of senile cataract, the rat model of selenium-induced cataract is often used to simulate senile cataract.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Optimization and Characterization of Low-Molecular-Weight Chitosan-Coated Baicalin mPEG-PLGA Nanoparticles for the Treatment of Cataract

Zhao

et al. 2022

Mol. Pharmaceutics

View full text Add to dashboard Cite

The present study was to evaluate the potential effectiveness of low-molecular-weight chitosan-coated baicalin methoxy poly(ethylene glycol)-poly(D,L-lactic-co-glycolic acid) (mPEG-PLGA) nanoparticles (BA LCH NPs) for the treatment of cataract. mPEG-PLGA NPs were optimized by the Box− Behnken design and the central composite design based on the encapsulation efficiency and drug loading. Then, the BA LCH NPs were characterized based on morphology, particle size, and zeta potentials. The analytical data of differential scanning calorimetry, X-ray diffraction, and transmission electron microscopy depicted the drug excipient compatibility. In vitro, we evaluated cell viability, cellular uptake, potential ocular irritation, transcorneal permeability, and the precorneal retention of BA LCH NPs. In vivo, the chronic selenium cataract model was selected to assess the therapeutic effect of BA LCH NPs. The size of BA LCH NPs was within the range from 148 to 219 nm and the zeta potential was 19−25 mV. Cellular uptake results showed that the fluorescence intensity of the preparations in each group increased with time, and the fluorescence intensity of the LCH NP group was significantly higher than that of the solution group. The optimized BA LCH NPs improved precorneal residence time without causing eye irritation and also showed a sustained release of BA through the cornea for effective management of cataract. Also, fluorescence tracking on the rabbit cornea showed increased corneal retention of the LCH NPs. In addition, the results of therapeutic efficacy demonstrated that BA LCH NPs can significantly reduce the content of malondialdehyde and enhanced the activities of catalase, superoxide dismutase, and glutathione peroxidase, which was comparable to positive control and better than the BA solution group. Thus, it can be inferred that the BA LCH NPs are a promising drug delivery system for enhancing the ophthalmic administration of BA to the posterior segment of the eye and improving cataract symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

“…First, the LCH coating enhances its binding to the ocular surface through electrostatic attraction and hydrogen bonding. Second, the interaction between the LCH coating and epithelial cells not only opens the cell bypass pathway to prepare for drug penetration but also promotes cell penetration of drugs. , …”

Section: Discussionmentioning

confidence: 99%

Optimization and Characterization of Low-Molecular-Weight Chitosan-Coated Baicalin mPEG-PLGA Nanoparticles for the Treatment of Cataract

Zhao

et al. 2022

Mol. Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…The same authors developed an approach with the same materials to deliver two drugs with anti-inflammatory properties for inflammatory treatment after intraocular surgery [ 60 ]. In this work, the authors proposed levofloxacin encapsulated into PLGA NPs.…”

Section: Routes Of Drugs Administrationmentioning

confidence: 99%

Polymeric Nanoparticles-Loaded Hydrogels for Biomedical Applications: A Systematic Review on In Vivo Findings

et al. 2022

View full text Add to dashboard Cite

Clinically available medications face several hurdles that limit their therapeutic activity, including restricted access to the target tissues due to biological barriers, low bioavailability, and poor pharmacokinetic properties. Drug delivery systems (DDS), such as nanoparticles (NPs) and hydrogels, have been widely employed to address these issues. Furthermore, the DDS improves drugs’ therapeutic efficacy while reducing undesired side effects caused by the unspecific distribution over the different tissues. The integration of NPs into hydrogels has emerged to improve their performance when compared with each DDS individually. The combination of both DDS enhances the ability to deliver drugs in a localized and targeted manner, paired with a controlled and sustained drug release, resulting in increased drug therapeutic effectiveness. With the incorporation of the NPs into hydrogels, it is possible to apply the DDS locally and then provide a sustained release of the NPs in the site of action, allowing the drug uptake in the required location. Additionally, most of the materials used to produce the hydrogels and NPs present low toxicity. This article provides a systematic review of the polymeric NPs-loaded hydrogels developed for various biomedical applications, focusing on studies that present in vivo data.

show abstract

“…According to the scope of action of these drugs, they can be divided into systemic treatments and local treatments. Topical treatments, such as eye drops, suspensions and ointments, are associated with fewer side effects than systemic treatments [5,20,21]. However, the corneal epithelium is the rate-limiting layer for hydrophilic drugs, and the corneal stroma is the rate-limiting layer for lipophilic drugs, resulting in limited corneal permeability.…”

Section: Improving Drug Corneal Permeabilitymentioning

confidence: 99%

“…Under current administration methods, such as eye drops, effective drug concentrations can remain sufficiently high at the site of the lesion for only a short time. Thus, administrations are frequently required to maintain effective drug concentrations at the target sites for long periods, which can reduce patient compliance and cause side effects such as ocular surface epithelial cell toxicity, corticosteroid-induced cataracts, and delayed epithelial healing [5,20,21]. For example, diclofenac sodium (DS), a nonsteroidal anti-inflammatory drug, is widely used to treat inflammation due to its potent inhibition of cyclooxygenase-2 (COX-2).…”

Section: Prolonging the Drug Effective Durationmentioning

confidence: 99%

Immune modulating nanoparticles for the treatment of ocular diseases

Fang

Liu

et al. 2022

J Nanobiotechnol

View full text Add to dashboard Cite

Ocular diseases are increasingly influencing people’s quality of life. Complicated inflammatory mechanisms involved in the pathogenic process of ocular diseases make inflammation-targeting treatment a potential therapeutic approach. The limited efficacy of conventional anti-inflammatory therapeutic strategies, caused by various objective factors, such as complex ocular biological barriers, and subjective factors, such as poor compliance, are promoting the development of new therapeutic methods. With the advantages of considerable tissue permeability, a controllable drug release rate, and selective tissue targeting ability, nanoparticles have successfully captured researchers’ attention and have become a research hotspot in treating ocular diseases. This review will focus on the advantages of nanosystems over traditional therapy, the anti-inflammation mechanisms of nanoparticles, and the anti-inflammatory applications of nanoparticles in different ocular diseases (ocular surface diseases, vitreoretinopathy, uveal diseases, glaucoma, and visual pathway diseases). Furthermore, by analyzing the current situation of nanotherapy and the challenges encountered, we hope to inspire new ideas and incentives for designing nanoparticles more consistent with human physiological characteristics to make progress based on conventional treatments. Overall, some progress has been made in nanoparticles for the treatment of ocular diseases, and nanoparticles have rather broad future clinical translation prospects.

show abstract

Development of a dual delivery of levofloxacin and prednisolone acetate via PLGA nanoparticles/ thermosensitive chitosan-based hydrogel for postoperative management: An in-vitro and ex-vivo study

Cited by 26 publications

References 47 publications

Optimization and Characterization of Low-Molecular-Weight Chitosan-Coated Baicalin mPEG-PLGA Nanoparticles for the Treatment of Cataract

Optimization and Characterization of Low-Molecular-Weight Chitosan-Coated Baicalin mPEG-PLGA Nanoparticles for the Treatment of Cataract

Polymeric Nanoparticles-Loaded Hydrogels for Biomedical Applications: A Systematic Review on In Vivo Findings

Immune modulating nanoparticles for the treatment of ocular diseases

Contact Info

Product

Resources

About